Kai Habben Selected Research

Insulin (Novolin)

12/2011

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kai Habben Research Topics

Disease

3	Neoplasms (Cancer) 01/2017 - 05/2007
2	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 07/2015
1	Hepatocellular Carcinoma (Hepatoma) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Dysphonia (Spastic Dysphonia) 07/2015
1	Fatigue 07/2015
1	Headache (Headaches) 07/2015
1	Hypertension (High Blood Pressure) 07/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2011
1	Ewing Sarcoma (Sarcoma, Ewing) 04/2010
1	Breast Neoplasms (Breast Cancer) 05/2007

Drug/Important Bio-Agent (IBA)

4	Monoclonal AntibodiesIBA 01/2017 - 04/2010
2	Bevacizumab (Avastin)FDA Link 01/2017 - 07/2015
2	TB-403IBA 01/2017 - 07/2015
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2017 - 07/2015
2	teprotumumabIBA 12/2011 - 04/2010
1	Sorafenib (BAY 43-9006)FDA Link 01/2017
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2011
1	Insulin (Novolin)FDA Link 12/2011
1	IGF Type 1 Receptor (IGF 1 Receptor)IBA 04/2010
1	Trastuzumab (Herceptin)FDA Link 05/2007
1	human ERBB2 proteinIBA 05/2007